Compare HP Inc (HPQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? HP Inc trades at $30.43 (market cap $27.62B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: HP Inc is far larger — about 5.7× Travere Therapeutics Inc. Common Stock's market cap, and HP Inc pays a 3.92% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HPQ | TVTX | |
|---|---|---|
Market Cap | $27.62B | $4.88B |
Volume | 12,820,066 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $35.48 | $67.52 |
52-Week Low | $18.20 | $26.79 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $33.79B | $5.01B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $30.46, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains stable cash flow generation ($460M net in 2025) and pays a $0.30 dividend, but faces PC market headwinds with 2027 industry volume declines projected. Valuation appears reasonable with P/E of 11.69 and P/S of 0.48, though negative shareholder equity raises concerns.
The outlook is mixed: attractive valuation and dividend yield support the stock, but PC market challenges and negative equity position create significant risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside potential amid industry uncertainty.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
